New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma.Results of the ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

The National Comprehensive Cancer Network ® (NCCN ® ) has recently added Lunsumio and Polivy to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) as a category 2A recommendation ...

Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel ...

Explore the evolving RVO treatment landscape from anti-VEGF breakthroughs to pipeline innovations addressing unmet needs in efficacy, safety, and dosing burden. Retinal Vein Occlusion care is entering ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Jun 16, 2025-- ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech is letting go of 143 employees who are based out of the company's ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets go of 143 workers at its headquarters in South San Francisco, according to ...